What Is The Current and Historic Market Size Analysis Of The D Dimer Testing Market?
The d dimer testing market has seen considerable growth due to a variety of factors.
•The market size for D dimer testing has seen unwavering growth over the past few years. Its value is expected to surge from $1.47 billion in 2024 to $1.54 billion in 2025, reporting a compound annual growth rate (CAGR) of 5.0%.
The development during the historical phase can be associated with the rise of thrombosis studies, enhancements in lab procedures, the confirmation of d-dimer as a significant marker through clinical testing, and modifications in diagnostic protocols.
What Are The Predictions for The D Dimer Testing Market Size In The Coming Years?
The d dimer testing market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, robust expansion is expected within the D dimer testing market, with a projected value of $1.9 billion by 2029, indicating a compound annual growth rate (CAGR) of 5.4%.
This anticipated growth during the forecast period is due to various factors, such as an increase in elderly demographics, advancements in point-of-care testing (POCT), incorporation into risk evaluation algorithms, heightened awareness through education campaigns, regulatory oversight and standardization. During the forecast period, prevalent trends are expected to include the integration of biomarkers for improved diagnostic capabilities, an emphasis on swift and precise results, the use of d-dimer testing in handling COVID-19, the advent of remote monitoring and home-based testing kits, perpetual monitoring, and ongoing testing.
Which Key Drivers Are Propelling The D Dimer Testing Market's Growth?
The escalation in cancer rates is slated to boost the progress of the d-dimer testing market. Cancer encompasses a range of diseases that can manifest in virtually any organ or tissue when abnormal cells multiply uncontrollably, crossing their typical boundaries, either metastasizing to other organs or infiltrating surrounding body parts. D-dimer testing primarily facilitates the diagnosis, monitoring, and treatment of cancer patients, evaluating the likelihood of blood clot formation. It keeps track of thrombotic events in a range of clinical contexts. For example, based on research released by the American Cancer Society, a health organization based in the U.S, in January 2022, it's expected that there will be 609,360 cancer-related deaths and 1.9 million fresh cancer cases in the U.S in 2022, which rounds up to about 1,670 deaths each day. As such, the rising incidence of cancer is propelling the expansion of the d-dimer testing market.
What Are The Key Segments Within The Global D Dimer Testing Market?
The D dimer testing market covered in this report is segmented –
1) By Test: Clinical Laboratory Tests, Point-Of-Care Tests
2) By Product: Analyzers, Reagents And Consumables
3) By Method: Enzyme-linked Immunosorbent Assay (ELISA), Latex-enhanced Immuno-turbidimetric Assays, Fluorescence Immunoassays, Other Testing Method
4) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Disseminated Intravascular Coagulation (DIC), Other Application
5) By End-User: Hospitals, Academic And Research Institutes, Diagnostic Centers, Other End-User
Subsegments:
1) By Clinical Laboratory Tests: Enzyme-Linked Immunosorbent Assay (Elisa), Chemiluminescent Immunoassay (CLIA), Latex Agglutination Assays, Other Laboratory Testing Methods
2) By Point-Of-Care Tests: Rapid Test Kits, Portable Testing Devices, Lateral Flow Assays, Other Point-Of-Care Testing Methods
Pre-Book The D Dimer Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The D Dimer Testing Market?
Key players in the D-dimer testing market are implementing a strategic collaboration strategy to secure exclusive rights to D-dimer testing solutions and attain a competitive advantage. Strategic collaborations involve companies utilizing each other's strengths and resources for mutual benefit and accomplishment. To illustrate, SphingoTec GmbH, a German biotechnology firm, recently coordinated with Rivaara Labs Pvt Ltd., an Indian medical laboratory and healthcare provider, in March 2022. Under this agreement, Rivaara is granted sole rights to promote and distribute SphingoTec's point-of-care tests with innovative biomarkers on the Indian subcontinent. These include proenkephalin (penKid) for evaluating kidney function, bioactive adrenomedullin (bio-ADM) for assessing endothelial function, and dipeptidyl peptidase 3 (DPP3) as a biomarker for cardiac depression. These advanced markers complement other frequently used parameters like procalcitonin, troponin, D-dimer, NT-proBNP, and TSH.
Who Are the Key Players in the D Dimer Testing Market?
Major companies operating in the D dimer testing market include:
• Kaiser Foundation Health Plan Inc.
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Siemens Healthcare GmbH
• Becton Dickinson And Company (BD)
• Laboratory Corporation
• Quest Diagnostics Inc.
• bioMérieux SA
• Beckman Coulter Inc.
• Quidel Corporation
• QuidelOrtho Corporation
• Sysmex Corporation
• Horiba Ltd.
• Werfen SA
• Helena Laboratories Corporation
• Abcam plc
• LumiraDx Limited
• Personalabs
• Sekisui Diagnostics LLC
• Diagnostica Stago S.A.S.
• RayBiotech Inc.
• CTK Biotech Inc.
• Diazyme Laboratories Inc.
• AdvaCare Pharma USA
• UCP Biosciences Inc.
• AccuBioTech Co Ltd.
• Response Biomedical Corporation
What are the Regional Insights into the D Dimer Testing Market?
North America was the largest region in the D dimer testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the D dimer testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
